Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Kai Yeung & Josh J Carlson. (2012) Clinical and economic review of erlotinib in non-small-cell lung cancer. Expert Review of Pharmacoeconomics & Outcomes Research 12:4, pages 411-423.
Read now
Read now
Articles from other publishers (12)
Anna Perzanowska, Agnieszka Fatalska, Grzegorz Wojtas, Andrzej Lewandowicz, Agata Michalak, Grzegorz Krasowski, Christoph H. Borchers, Michal Dadlez & Dominik Domanski. (2018) An MRM-Based Cytokeratin Marker Assay as a Tool for Cancer Studies: Application to Lung Cancer Pleural Effusions. PROTEOMICS - Clinical Applications 12:2, pages 1700084.
Crossref
Crossref
P.A. Singleton, T. Mirzapoiazova, R. Hasina, R. Salgia & J. Moss. (2014) Increased μ-opioid receptor expression in metastatic lung cancer. British Journal of Anaesthesia 113, pages i103-i108.
Crossref
Crossref
Frances E. Lennon, Tamara Mirzapoiazova, Bolot Mambetsariev, Valeriy A. Poroyko, Ravi Salgia, Jonathan Moss & Patrick A. Singleton. (2014) The Mu Opioid Receptor Promotes Opioid and Growth Factor-Induced Proliferation, Migration and Epithelial Mesenchymal Transition (EMT) in Human Lung Cancer. PLoS ONE 9:3, pages e91577.
Crossref
Crossref
David M. Lonard & Bert W. O’Malley. 2014. Genetic Steroid Disorders. Genetic Steroid Disorders
301
312
.
Siying Wang, Liubao Peng, Jianhe Li, Xiaohui Zeng, Lihui Ouyang, Chongqing Tan & Qiong Lu. (2013) A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer. PLoS ONE 8:3, pages e55917.
Crossref
Crossref
Mi Jin Kim, Hyeong Chan Shin, Kyeong Cheol Shin & Jae Y. Ro. (2013) Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens. Annals of Diagnostic Pathology 17:1, pages 85-90.
Crossref
Crossref
David M. Lonard & Bert W. O'Malley. (2012) Nuclear receptor coregulators: modulators of pathology and therapeutic targets. Nature Reviews Endocrinology 8:10, pages 598-604.
Crossref
Crossref
Ching-Chan Lin, Te-Chun Hsia & Chun-Ru Chien. (2012) 3rd line Erlotinib for lung cancer in Asia may be as cost-effective as in the Western world. Lung Cancer 76:3, pages 499-500.
Crossref
Crossref
Shoude Zhang, Jia Chen, Hua Jiang, Haina Ma & Beibei Yang. (2012) Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis. European Journal of Clinical Pharmacology 68:5, pages 561-569.
Crossref
Crossref
Mathilda L. Bongers, Veerle M.H. Coupé, Elise P. Jansma, Egbert F. Smit & Carin A. Uyl-de Groot. (2012) Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer. PharmacoEconomics 30:1, pages 17-34.
Crossref
Crossref
J.E. Poquet Jornet, F.J. Carrera-Hueso, J.M. Gasent Blesa & M. Peris Godoy. (2011) Aspectos farmacoeconómicos de los citostáticos orales. Farmacia Hospitalaria 35, pages 25-31.
Crossref
Crossref
Lisa M. Stoll, Michael W. Johnson, Edward Gabrielson, Fredrick Askin, Douglas P. Clark & Qing Kay Li. (2010) The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathology 118:6, pages 441-449.
Crossref
Crossref